Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 8/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 6/20 | 0.36 |
| ▸ | HTR1B | P28222 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1630736 | 0.78 | PGR (0.63) | PGRNR3C1NR3C2BRPF1ALDH1A1 | |
| SCHEMBL10095643 | 0.75 | PTGS2 (0.46) | PGRNR3C1NR3C2BRPF1AR | |
| Hydrochloric Acid SCHEMBL28216721 | 0.68 | CA2 (0.47) | NR3C2BRPF1ALDH1A1HTR1BTP53 | |
| SCHEMBL10095641 | 0.64 | PLAU (0.44) | PGRBRPF1ALDH1A1AR | |
| SCHEMBL18424803 | 0.63 | ACLY (0.48) | PGRNR3C1NR3C2BRPF1ALDH1A1 | |
| SCHEMBL29756248 | 0.62 | DYRK1A (0.50) | HTR1B | |
| SCHEMBL1629519 | 0.61 | PGR (0.62) | PGRNR3C1NR3C2BRPF1ALDH1A1 | |
| SCHEMBL21646342 | 0.60 | HTR1B (0.49) | ALDH1A1HTR1B | |
| SCHEMBL1630908 | 0.60 | PGR (0.67) | PGRNR3C1NR3C2BRPF1AR | |
| SCHEMBL3590172 | 0.60 | ALDH1A1 (0.55) | PGRBRPF1ALDH1A1KAT2BBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979314-B1 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | LILLY CO ELI (US) | 2013-01-09 | — | — | EP | disclosed |
| US-7932284-B2 | Indole sulfonamide modulators of progesterone receptors | ELI LILLY AND COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | ELI LILLY AND COMPANY | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | PGR, NPSR1, PRLHR | PGR 1/4885NR3C1 63/4885NR3C2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.